185 related articles for article (PubMed ID: 23719746)
1. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
Cancer; 2013 Sep; 119(17):3242-50. PubMed ID: 23719746
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
3. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Metzger R; Leichman CG; Danenberg KD; Danenberg PV; Lenz HJ; Hayashi K; Groshen S; Salonga D; Cohen H; Laine L; Crookes P; Silberman H; Baranda J; Konda B; Leichman L
J Clin Oncol; 1998 Jan; 16(1):309-16. PubMed ID: 9440758
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
Lin CS; Liu TC; Lai JC; Yang SF; Tsao TC
Int J Med Sci; 2017; 14(13):1410-1417. PubMed ID: 29200955
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
Choueiri MB; Shen JP; Gross AM; Huang JK; Ideker T; Fanta P
PLoS One; 2015; 10(6):e0126898. PubMed ID: 26083491
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.
Kim MH; Zhang X; Jung M; Jung I; Park HS; Beom SH; Kim HS; Rha SY; Kim H; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Noh SH; Chung HC
Cancer Res Treat; 2019 Apr; 51(2):819-831. PubMed ID: 30282452
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
9. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
Kao SC; Lee K; Klebe S; Henderson D; McCaughan B; Vardy J; Clarke S; van Zandwijk N
Clin Lung Cancer; 2013 Mar; 14(2):164-71. PubMed ID: 23085037
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Uchida K; Danenberg PV; Danenberg KD; Grem JL
BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.
Deng Q; Yang H; Lin Y; Qiu Y; Gu X; He P; Zhao M; Wang H; Xu Y; Lin Y; Jiang J; He J; Zhou JX
Int J Clin Exp Pathol; 2014; 7(12):8312-21. PubMed ID: 25674197
[TBL] [Abstract][Full Text] [Related]
14. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
Colbert LE; Fisher SB; Hardy CW; Hall WA; Saka B; Shelton JW; Petrova AV; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
Cancer; 2013 Sep; 119(17):3148-55. PubMed ID: 23720157
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
[TBL] [Abstract][Full Text] [Related]
16. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Maithel SK; Coban I; Kneuertz PJ; Kooby DA; El-Rayes BF; Kauh JS; Sarmiento J; Staley CA; Volkan Adsay N
Ann Surg Oncol; 2011 Sep; 18(9):2699-705. PubMed ID: 21360249
[TBL] [Abstract][Full Text] [Related]
18. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
Li S; Zhu L; Yao L; Xia L; Pan L
BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
[TBL] [Abstract][Full Text] [Related]
19. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
20. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
